CN105503695A - Pharmaceutical composition for treating diabetes - Google Patents
Pharmaceutical composition for treating diabetes Download PDFInfo
- Publication number
- CN105503695A CN105503695A CN201610028829.1A CN201610028829A CN105503695A CN 105503695 A CN105503695 A CN 105503695A CN 201610028829 A CN201610028829 A CN 201610028829A CN 105503695 A CN105503695 A CN 105503695A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- diabetes
- compound
- treatment
- thinner
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
Abstract
The invention relates to a pharmaceutical composition for treating diabetes, which comprises an effective amount of compounds and a pharmaceutically acceptable carrier, wherein the compounds are disclosed in the specification. The compounds have obvious effects on diabetes, and can be developed into a clinically effective new pharmaceutical composition.
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to a kind of pharmaceutical composition for the treatment of diabetes.
Background technology
Show at " national Diabetes Epidemiological Investigation (2007-2008) ", in the crowd of China more than 20 years old, the morbidity of diabetes men and women property reaches 10.6% and 8.8% respectively, overall diabetes prevalence is 9.7%, thus, extrapolate the total number of patients of national diabetes and be about 9,200 ten thousand people.And more seriously, show in this investigation, the morbidity of pre-diabetes, up to 15.5%, extrapolates number of patients about 1.48 hundred million people of national pre-diabetes.By compared with data in the past, middle-aged population suffers from the number of diabetes to be increased more obvious, and the morbidity of crowd's diabetes of 25 ~ 34 years old adds 8 times.But for this problem, still lack effective medicine and methods for the treatment of clinically.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition for the treatment of diabetes.
In order to realize object of the present invention, the invention provides a kind of compound for the treatment of diabetes, this compound has having structure:
The present invention also provides a kind of pharmaceutical composition for the treatment of diabetes, and described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
Preferably, described pharmaceutically acceptable carrier is thinner, disintegrating agent, tackiness agent, lubricant, stablizer or corrigent.
Preferably, described thinner is sugar derivatives, starch derivative or derivatived cellulose.
Preferably, described thinner is lactose.
Preferably, described pharmaceutical composition is powder, microgranules, granule, capsule or tablet.
The present invention also provides the purposes of compound in the medicine of preparation treatment diabetes, and this compound has having structure:
Term used herein " pharmaceutically acceptable " refers to not eliminate the biologic activity of compound as herein described or the material of character, as carrier or thinner.This kind of material is applied to and individual does not cause undesirable biological action or not with harmful way and any component interaction comprised in its composition.
" pharmaceutically acceptable carrier " comprises any and all solvents as the term is employed herein, dispersion medium, coating material, tensio-active agent, antioxidant, sanitas (such as antiseptic-germicide, anti-mycotic agent), isotonic agent, absorption delay agent, salt, sanitas, drug stabilizing agent, tackiness agent, vehicle, disintegrating agent, lubricant, sweeting agent, correctives, dyestuff etc. and its combination, this is well-known to those skilled in the art (for example, see Remington'sPharmaceuticalSciences, 18thEd.MackPrintingCompany, 1990, pp.1289-1329).Except with except the inconsistent carrier of activeconstituents, consider to use any conventional carrier in treatment or pharmaceutical composition.
Compound of the present invention, for the Be very effective of diabetes, can be developed to pharmaceutical composition effectively new clinically.
Embodiment
Below by way of the description of embodiment, the invention will be further described, but this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, various amendment or improvement can be made, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.
Experimental example
The structural formula of target compound is:
Diabetes B Establishment of Rat Model
SPF level SD male rat, body weight (140 ± 10) g, feeding environment temperature is 20-25 DEG C, and relative humidity 50%-60%, 12/12h circadian is fed.Conventional raising 1 week, then separate normal group at random, normal group 10 animals, give normal diet, other animals give high lipid food.High lipid food is purchased from Beijing HFK Bio-Technology Co., Ltd., and SCXK (capital) 2009-0004, is maintained feed etc. formed by lard, yolk powder, sucrose, basis.
Buffer preparation: the citric acid-sodium citrate buffer of preparation pH4.4-4.6, containing 1.07g citric acid and 1.44g Trisodium Citrate in about every 100m1 buffered soln, 4 DEG C save backup;
1% streptozotocin (STZ) is prepared: use above-mentioned buffered soln, be dissolved in 100ml buffer preparation, matching while using, lucifuge, cold operation by 1gSTZ;
STZ prerun: during high fat is fed, carry out pre-modeling with STZ dosage 25mg/kg, 30mg/kg, 35mg/kg, 40mg/kg, the optimal dosage being specified to mould is 30mg/kg;
Injection STZ: high fat is fed 8 weeks, and fasting is after 12 hours, and high fat group rat gives abdominal injection by STZ30mg/kg, after 6 hours, the G/W of supplementary 5% 12 hours, changes thereafter with ortho-water;
Blood sugar test: after one week, adopts Abbott Laboratories' blood glucose meter and supporting blood sugar test paper, detects the fasting overnight high fat group rat fasting blood-glucose value of 10 hours, if blood glucose value >=11.1mmol/L and modeling success;
Complement SZT: rat fasting plasma glucose not being reached to 11.1mmol/L carries out complement STZ, after one week, if blood glucose value >=11.1mmol/L, then Cheng Mo enters group, does not reach person yet, gives up.
Carrying out random packet with body weight to becoming mould rat according to fasting blood sugar, being divided into three groups, often organize 10, the equal no difference of science of statistics of body weight (P>0.05): normal group, model group, administration group.Each group of dosage is as follows: normal group and model group, gives physiological saline gavage 1mL/100g body weight; Administration group, the target compound of 0.005g adds 1000mL normal saline and becomes suspension, gives gavage 1mL/100g body weight.1 times/day, successive administration records blood glucose value in 4 weeks, the results are shown in following table.
| Group | Blood glucose value (mmol/L) |
| Normal group | 5.31±0.83 |
| Model group | 15.72±1.08 |
| Target compound | 8.92±0.95 |
Claims (7)
1. treat a compound for diabetes, it is characterized in that, this compound has having structure:
2. treat a pharmaceutical composition for diabetes, it is characterized in that, described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
3. the pharmaceutical composition for the treatment of diabetes according to claim 2, is characterized in that, described pharmaceutically acceptable carrier is thinner, disintegrating agent, tackiness agent, lubricant, stablizer or corrigent.
4. the pharmaceutical composition for the treatment of diabetes according to claim 3, is characterized in that, described thinner is sugar derivatives, starch derivative or derivatived cellulose.
5. the pharmaceutical composition for the treatment of diabetes according to claim 4, is characterized in that, described thinner is lactose.
6. the pharmaceutical composition for the treatment of diabetes according to claim 3, is characterized in that, described pharmaceutical composition is powder, microgranules, granule, capsule or tablet.
7. the purposes of compound in the medicine of preparation treatment diabetes, it is characterized in that, this compound has having structure:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610028829.1A CN105503695A (en) | 2016-01-16 | 2016-01-16 | Pharmaceutical composition for treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610028829.1A CN105503695A (en) | 2016-01-16 | 2016-01-16 | Pharmaceutical composition for treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105503695A true CN105503695A (en) | 2016-04-20 |
Family
ID=55712066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610028829.1A Pending CN105503695A (en) | 2016-01-16 | 2016-01-16 | Pharmaceutical composition for treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105503695A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107198692A (en) * | 2017-03-01 | 2017-09-26 | 长沙博海生物科技有限公司 | Application of the Acankoreanogenia A in treatment diabetes medicament is prepared |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1802353A (en) * | 2002-12-30 | 2006-07-12 | 细胞基因公司 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses |
| CN101326177A (en) * | 2005-11-01 | 2008-12-17 | 詹森药业有限公司 | Dihydroisoindolones as allosteric modulators of glucokinase |
| US20090202525A1 (en) * | 2005-11-01 | 2009-08-13 | Haiyan Bian | Dihydroisoindolones as allosteric modulators of glucokinase |
| CN104211633A (en) * | 2014-08-12 | 2014-12-17 | 中国科学院微生物研究所 | Isoindole compound and application thereof |
-
2016
- 2016-01-16 CN CN201610028829.1A patent/CN105503695A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1802353A (en) * | 2002-12-30 | 2006-07-12 | 细胞基因公司 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses |
| CN101326177A (en) * | 2005-11-01 | 2008-12-17 | 詹森药业有限公司 | Dihydroisoindolones as allosteric modulators of glucokinase |
| US20090202525A1 (en) * | 2005-11-01 | 2009-08-13 | Haiyan Bian | Dihydroisoindolones as allosteric modulators of glucokinase |
| CN104211633A (en) * | 2014-08-12 | 2014-12-17 | 中国科学院微生物研究所 | Isoindole compound and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 胡晨明: "新型3-芳基异吲哚酮化合物的设计、合成与抗癌活性研究", 《吉林大学博士学位论文》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107198692A (en) * | 2017-03-01 | 2017-09-26 | 长沙博海生物科技有限公司 | Application of the Acankoreanogenia A in treatment diabetes medicament is prepared |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Raether et al. | Nitroheterocyclic drugs with broad spectrum activity | |
| US9138438B2 (en) | Method for protecting a retinal neuronal cell | |
| SG193379A1 (en) | Dosing regimens for the treatment of fabry disease | |
| JP7041322B2 (en) | 2,3,5-substituted thiophene compounds for the prevention, amelioration or treatment of breast cancer | |
| JP7222042B2 (en) | Method of using 5'-adenosine diphosphate ribose (ADPR) | |
| CZ355897A3 (en) | Method of treating mania and bipolar disturbances | |
| JP2020528928A (en) | How to use dipivefrine | |
| CN105503695A (en) | Pharmaceutical composition for treating diabetes | |
| EP3324968B1 (en) | Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of cancer | |
| CN105294560A (en) | Pharmaceutical composition for treating diabetes type II | |
| JP5961034B2 (en) | Stabilization method | |
| KR102204204B1 (en) | Composition for treatment of muscular disorders | |
| CN113423404A (en) | Xanthine derivative pharmaceutical composition and preparation method thereof | |
| EP3322402B1 (en) | Compositions of midazolam for buccal administration in the treatment of seizures to obtain rapid onset of action | |
| TWI544928B (en) | USE OF ERGOSTATRIEN-3β-OL IN THE MANUFACTURE OF MEDICAMENT | |
| US11723890B2 (en) | Methods of treatment using an mTORC1 modulator | |
| US11246855B1 (en) | Pharmaceutical composition to treat health conditions associated with elevated glucose levels | |
| US20160143885A1 (en) | Treatment Method for Steroid Responsive Dermatoses | |
| TWI794847B (en) | Composition for reducing metabolic syndrome and application thereof | |
| EP4299059A1 (en) | Composition for the treatment of tinnitus | |
| US20220362202A1 (en) | Drug For Treating And Preventing Dementia | |
| WO2023180956A1 (en) | Methods of using avermectin compositions for the treatment of spasticity and dosing regimens | |
| CN112294808A (en) | Application of hydrochloric acid demethyleneberberine acetate in preparation of medicine for preventing or treating drug-induced liver injury | |
| CN111973729A (en) | Application of lamiophlomis rotata preparation in preparation of bortezomib synergist | |
| JPH0892089A (en) | Medicine for dry vagina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160420 |